{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:27:39Z","timestamp":1778776059034,"version":"3.51.4"},"reference-count":34,"publisher":"Media Sphere Publishing House","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2026,5,14]]},"abstract":"<jats:p>Multiple randomized controlled trials (RCTs), systematic reviews, meta-analyses, and multidisciplinary studies in both hospital and outpatient settings have demonstrated the high efficacy and safety of choline alfoscerate (CA) therapy for patients with mild and moderate cognitive impairment (MCI), amnestic cognitive impairment, predementia cognitive impairment in Alzheimer's disease (AD), elderly individuals, and first-degree relatives of patients with AD as preventive therapy. The Russian CA drug Cereton is available in several formulations, including solutions for intravenous and intramuscular injection, capsules, and an oral solution, enabling individualized treatment approaches. In hospital settings, injection therapy with Cereton is administered for 10 days, followed by an oral course lasting up to 60 days. The duration and dosage of Cereton oral solution and capsules are determined by patient age and clinical condition. The oral solution is approved for use in children from 6 years of age, and the capsules are approved for use in children from 11 years of age, with treatment courses lasting up to 60 days. Cereton therapy consists of two stages: initial intravenous or intramuscular administration, followed by oral administration of capsules or the oral solution. The drug is generally well-tolerated, with adverse events being infrequent and minor.<\/jats:p>","DOI":"10.17116\/jnevro202612604148","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:54:56Z","timestamp":1778774096000},"page":"48","source":"Crossref","is-referenced-by-count":0,"title":["Choline alfoscerate in the treatment of cognitive impairment"],"prefix":"10.17116","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3726-0730","authenticated-orcid":false,"given":"O.A.","family":"Shavlovskaya","sequence":"first","affiliation":[{"name":"International University of Restorative Medicine","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202612604148-1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-140150"},{"key":"key-10.17116\/jnevro202612604148-2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.07.003"},{"key":"key-10.17116\/jnevro202612604148-3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1148166"},{"key":"key-10.17116\/jnevro202612604148-4","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-221189"},{"key":"key-10.17116\/jnevro202612604148-5","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2025.1613566"},{"key":"key-10.17116\/jnevro202612604148-6","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy132"},{"key":"key-10.17116\/jnevro202612604148-7","doi-asserted-by":"publisher","DOI":"10.46393\/27129675_2024_1_6"},{"key":"key-10.17116\/jnevro202612604148-8","doi-asserted-by":"publisher","DOI":"10.3233\/jad-190623"},{"key":"key-10.17116\/jnevro202612604148-9","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60060925"},{"key":"key-10.17116\/jnevro202612604148-10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2022.06.006"},{"key":"key-10.17116\/jnevro202612604148-11","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-024-05366-7"},{"key":"key-10.17116\/jnevro202612604148-12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16131"},{"key":"key-10.17116\/jnevro202612604148-13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051664"},{"key":"key-10.17116\/jnevro202612604148-14","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-024-05531-y"},{"key":"key-10.17116\/jnevro202612604148-15","unstructured":""},{"key":"key-10.17116\/jnevro202612604148-16","unstructured":"Batysheva TN, Nesterova OS, Otcheskaya OV, et al. The use of Cereton in patients with moderate vascular cognitive disorders. A Difficult Patient. 2009;7(4-5):10-12. (In Russ.)"},{"key":"key-10.17116\/jnevro202612604148-17","unstructured":"Kamchatnov PR, Abusueva BA, Evzel\u2019man MA, et al. Efficacy of cereton in acute ischemic stroke: results of the trial SOLNTSE. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(3-2):10-14. (InRuss.)"},{"key":"key-10.17116\/jnevro202612604148-18","unstructured":"Kolykhalov IV, Gavrilova SI. Prolonged alfoscerate effects in patients with the syndrome of amnestic mild cognitive impairment. Pacific Medical Journal. 2019;1(75):18-22. (In Russ.)"},{"key":"key-10.17116\/jnevro202612604148-19","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20181185145"},{"key":"key-10.17116\/jnevro202612604148-20","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20171176121-27"},{"key":"key-10.17116\/jnevro202612604148-21","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro201411412178-83"},{"key":"key-10.17116\/jnevro202612604148-22","unstructured":"Selezneva ND, Kolykhalov IV, Gavrilova SI. A Comparative prospective multidisciplinary research of efficiency of choline alphoscerate in prevention of cognitive deficiency progressing in relatives of patients with Alzheimer\u2019s disease. Psychiatry. 2020;18(1):6-15. (In Russ.)"},{"key":"key-10.17116\/jnevro202612604148-23","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202412404292"},{"key":"key-10.17116\/jnevro202612604148-24","doi-asserted-by":"publisher","DOI":"10.24411\/2071-5315-2020-12193"},{"key":"key-10.17116\/jnevro202612604148-25","doi-asserted-by":"publisher","DOI":"10.24412\/2226-0757-2025-13273"},{"key":"key-10.17116\/jnevro202612604148-26","unstructured":"Gainetdinova DD, Agranovich OV, Nemkova SA, et al. The results of a multicenter, double-blind, randomized, placebo-controlled clinical trial of the efficacy, safety and tolerability of the drug Cereton in the treatment of cognitive impairment in children in the recovery period of traumatic brain injury and hemorrhagic stroke. Effective Pharmacotherapy. 2024;20(14):6-14. (In Russ.)"},{"key":"key-10.17116\/jnevro202612604148-27","doi-asserted-by":"publisher","DOI":"10.1007\/s11055-010-9377-2"},{"key":"key-10.17116\/jnevro202612604148-28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1649661"},{"key":"key-10.17116\/jnevro202612604148-29","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202512508116"},{"key":"key-10.17116\/jnevro202612604148-30","doi-asserted-by":"publisher","DOI":"10.46393\/27129675_2025_1_40-46"},{"key":"key-10.17116\/jnevro202612604148-31","doi-asserted-by":"publisher","DOI":"10.26442\/20751753.2024.2.202674"},{"key":"key-10.17116\/jnevro202612604148-32","unstructured":"Instructions for the medical use of Cereton, 250 mg\/ml (solution for intravenous and intramuscular administration). Accessed October 17, 2025. https:\/\/grls.minzdrav.gov.ru\/Grls_View_v2.aspx?routingGuid=593686c6-047b-4fee-b7d9-2b69456e7baa"},{"key":"key-10.17116\/jnevro202612604148-33","unstructured":"Instructions for the medical use of Cereton, 400 mg (capsules). Accessed April 17, 2025. https:\/\/grls.minzdrav.gov.ru\/Grls_View_v2.aspx?routingGuid=b4e64d1b-4f5f-4147-9e02-82c3a3eb2f5f"},{"key":"key-10.17116\/jnevro202612604148-34","unstructured":"Instructions for the medical use of Cereton (oral solution). Accessed January 26, 2024. https:\/\/grls.minzdrav.gov.ru\/Grls_View_v2.aspx?routingGuid=0cc21f6d-74e4-41bb-8a7c-1883208947b0"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:55:19Z","timestamp":1778774119000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2026\/4\/1199772982026041048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5,14]]}},"alternative-id":["10.17116\/jnevro202612604148"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202612604148","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}